Planning Capital Management Corporation’s Viking Therapeutics VKTX Stock Holding History

Planning Capital Management Corporation’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$64	Buy	+1	New	+$59	﹤0.01%	732

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Planning Capital Management Corporation's VKTX Position: Q3 2024 in Review

Planning Capital Management Corporation opened a new position in Viking Therapeutics (VKTX) in Q3 2024: 1 share worth $64. The stake represents ﹤0.01% of the portfolio and ranks #732 among its holdings.

422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

Planning Capital Management Corporation held 1 share of Viking Therapeutics worth $64 as of Q3 2024.
Viking Therapeutics was a new Planning Capital Management Corporation position in Q3 2024.
Viking Therapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #732 holding.
422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.